Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (27134)	1/2/1999 2:14:00 PM
From: aknahow	Respond to of 32384

Can't put domicile issue to bed when I want other biotechs to wake up, get out of bed and address this issue. Yes, it's a done deal for one biotech but I think it could be a real plus for others which are about to generate earnings. CORR and LGND are just two that I think should at least seriously consider a change in domicile. BTW agree on Rubin.

To: Arthur Radley who wrote (27134)	1/3/1999 12:02:00 PM
From: aknahow	Respond to of 32384

Keeping something out of bed, I offer this statement from a biotech's annual report. Not LGND nor XOMA but it could be anyones. This company is on the verge of profitability. "The Company will need to raise substantial additional funds in the future, and there can be no assurance that such funds will be available on favorable terms, if at all, if such funds are unavailable, the Company may need to delay or curtail its research and development activities to a significant extent." From 1997 CORR annual report. Boilerplate, sure but true nonetheless of many biotechs. This is a very good reason for making every dollar earned outside the U.S. go farther. A change in domicile can help.